Product

LBL-019

Aliases

LBL-019 Injection

1 clinical trial

1 indication

Indication

Advanced Malignant Tumors

Clinical trial

A Multicenter, Open Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of LBL-019 Monotherapy or Combination Anti-PD-1 Antibody in Patients With Advanced Malignant Tumors

Status: Recruiting, Estimated PCD: 2025-03-22